Van de Water, W
Safety Profile The most common adverse events documented across retatrutide results data were gastrointestinal in nature, with incidence increasing at higher doses: Nausea: 6-31% (dose-dependent), primarily during escalation periods Diarrhea: 6-25%, generally mild to moderate Vomiting: 0-16%, occurring mainly in the first weeks of each dose increase Decreased appetite: 3-19%, which contributed to the weight reduction effect Constipation: 3-12%, consistent with GLP-1 receptor-mediated gastric slowing Serious adverse events were rare across all cohorts
Since then, RSL3 was described as an inhibitor of GPX4 and Erastin was shown to inhibit the Xc- transport system, also called the cystine/glutamate antiporter
Add a serving of baked white fish or tofu
Factors such as the underlying cause of your deficiency, your age, overall health, and your medical history all play a role in determining the best treatment plan for you
People carrying null or reduced-function variants may retain more mercury from the same exposure, which helps explain individual differences in susceptibility
